Fragmin for VTE in cancer patients

The licence for Fragmin (dalteparin sodium) has been extended to include use in patients with solid tumours for the treatment of symptomatic venous thromboembolism (VTE) and the prevention of recurrence.

Fragmin may now be used for up to six months with a recommended dose of 200 international units/kg once daily for the first month and 150 international units/kg daily for the proceeding months. The dose will need to be adjusted in patients with significant renal failure or chemotherapy-induced thrombocytopenia.

View Fragmin drug record

Further information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases